Fibrosis therapeutic treatment in a muscular dystrophy context (Ref.TEC0051)

A palliative treatment for fibrosis in a Muscular Dystrophy context consisting in an antago-miRNA that effectively enhances tissue regeneration and ameliorates fibrosis. Allows for a slower development of the illness and improves patient's quality of life. We are looking for a partner to continue the preclinical experiments and/or license the patent for clinical development.

Fibrosis therapeutic treatment in a muscular dystrophy context
Ref: 
TEC0051 / P0016